Spots Global Cancer Trial Database for Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
Official Title: Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study
Study ID: NCT01082809
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
Detailed Description: Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: multicenter, multinational study
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Samsung Medical Center, Seoul, , Korea, Republic of
Contact Details
Name: Ho yeong Lim, M.D,Ph.D
Affiliation: Samsung Medical Center, Seoul, Korea
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
